Ticagrelor in Patients with Stable Coronary Disease and Diabetes
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events. Whether adding ticagrelor to aspirin improves outcomes in this population is unclear. METHODS: In this randomized, double-blind trial, we assigned patients who were 50 years of age or older and who had stable coronary artery disease and type 2 diabetes mellitus to receive either ticagrelor plus aspirin or placebo plus aspirin. Patients with previous myocardial infarction or stroke were excluded. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety outcome was major bleeding as defined by the Thrombolysis in Myocardial Infarction (TIMI) criteria. RESULTS: A total of 19,220 patients underwent randomization. The median follow-up was 39.9 months. Permanent treatment discontinuation was more frequent with ticagrelor than placebo (34.5% vs. 25.4%). The incidence of ischemic cardiovascular events (the primary efficacy outcome) was lower in the ticagrelor group than in the placebo group (7.7% vs. 8.5%; hazard ratio, 0.90; 95% confidence interval [CI], 0.81 to 0.99; P = 0.04), whereas the incidence of TIMI major bleeding was higher (2.2% vs. 1.0%; hazard ratio, 2.32; 95% CI, 1.82 to 2.94; P<0.001), as was the incidence of intracranial hemorrhage (0.7% vs. 0.5%; hazard ratio, 1.71; 95% CI, 1.18 to 2.48; P = 0.005). There was no significant difference in the incidence of fatal bleeding (0.2% vs. 0.1%; hazard ratio, 1.90; 95% CI, 0.87 to 4.15; P = 0.11). The incidence of an exploratory composite outcome of irreversible harm (death from any cause, myocardial infarction, stroke, fatal bleeding, or intracranial hemorrhage) was similar in the ticagrelor group and the placebo group (10.1% vs. 10.8%; hazard ratio, 0.93; 95% CI, 0.86 to 1.02). CONCLUSIONS: In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin. (Funded by AstraZeneca; THEMIS ClinicalTrials.gov number, NCT01991795.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, the addition of ticagrelor to aspirin reduced the risk of ischemic cardiovascular events compared with aspirin alone in people with diabetes and stable coronary artery disease (201,202).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [201]
In the citing paper
“However, a higher incidence of major bleeding, including intracranial hemorrhage, was noted with dual antiplatelet therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [201]
In the citing paper
“Similarly, the addition of ticagrelor to aspirin reduced the risk of ischemic cardiovascular events compared with aspirin alone in people with diabetes and stable coronary artery disease (189,190).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [189]
In the citing paper
“Thus, an unfavourable benefit-risk profile is associated with adding ticagrelor to ASA in this setting.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [302]
In the citing paper
“Over a median 3.3 years of follow-up, the primary efficacy outcome of CV death, MI, or stroke showed a marginal 10% RR reduction by ticagrelor vs. placebo, while both Thrombolysis in Myocardial Infarction (TIMI) major and intracranial bleeding were significantly increased.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [302]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Self-citationLong-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999
Self-citationTwelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409312 · Cited by 1,928
Self-citationPrasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874
Self-citationBhatt, D. L., Flather, M. D., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.03.025 · Cited by 805
Self-citationVranckx, P., Valgimigli, M., Jüni, P., Hamm, C., Steg, P. G., Heg, D., van Es, G. A., McFadden, E. P., Onuma, Y., van Meijeren, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31858-0 · Cited by 791
Self-citation
Cited by
Items 101–200 of 365
A Comprehensive Review of the Pleiotropic Effects of Ticagrelor
Triska, J., Maitra, N. S., Deshotels, M. R., Haddadin, F. I., Angiolillo, D. J., Vilahur, G., Jneid, H. M., Atar, D., & Birnbaum, Y. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07373-5 · Cited by 29
Pham, V., Moroni, A., Gall, E., Benedetti, A., Zivelonghi, C., & Picard, F. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082833 · Cited by 28
Vora, J. P., Cherney, D. Z. I., Kosiborod, M., Spaak, J., Kanumilli, N., Khunti, K., Lam, C. S. P., Bachmann, M., Fenici, P., & the CaReMe Global Alliance (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15485 · Cited by 32
Review of the Ticagrelor Trials Evidence Base
Herron, G. C., & Bates, E. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031606 · Cited by 27
Soto, L. G. D. L. P., Gutierrez-Uribe, J. A., Sharma, A. K., & Ramírez‐Jiménez, A. K. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.035 · Cited by 19
González‐Juanatey, C., Anguita-Sánchez, M. P., Barrios, V., Nuñez-Gil, I. J., Gómez‐Doblas, J. J., García–Moll, X., Gormaz, C. L., Rollán-Gómez, M. J., Peral-Disdier, V., Martínez‐Dolz, L., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165218 · Cited by 22
Birnbaum, Y., Chen, H., Tran, D., Nylander, S., & Ye, Y. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07222-x · Cited by 21
Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions
Canonico, M. E., Piccolo, R., Avvedimento, M., Leone, A., Esposito, S., Franzone, A., Giugliano, G., Gargiulo, G., Hess, C. N., Berkowitz, S. D., et al. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10040164 · Cited by 24
Zhu, H., Xu, X., Fang, X., Fei, Y., Song, L., Gao, B., Tong, G., Zhou, L., Chen, T., & Huang, J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019184 · Cited by 18
Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
Bergmark, B. A., Bhatt, D. L., Steg, P. G., Budaj, A., Storey, R. F., Gurmu, Y., Kuder, J., Im, K., Magnani, G., Ophuis, T. O., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020446 · Cited by 19
Self-citationGonzález‐Juanatey, C., Anguita-Sánchez, M. P., Barrios, V., Nuñez-Gil, I. J., Gómez-Doblas, J. J., García–Moll, X., Gormaz, C. L., Rollán-Gómez, M. J., Peral-Disdie, V., Martínez‐Dolz, L., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263277 · Cited by 16
Aspirin at 120: Retiring, recombining, or repurposing?
Patrono, C., & Rocca, B. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12516 · Cited by 16
Antiplatelet therapy around CABG: the latest evidence
Sandner, S. E., Redfors, B., & Gaudino, M. F. L. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001078 · Cited by 15
Ahmed, R., de Souza, R. J., Li, V., Banfield, L. E., & Anand, S. S. (2024) · Diabetologia · doi:10.1007/s00125-023-06052-w · Cited by 16
Franchi, F., Rollini, F., Been, L. F., Briceno, M., Maaliki, N., Wali, M., Rivas, A., Pineda, A. M., Suryadevara, S., Soffer, D. E., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.048770 · Cited by 15
Lackey, L. G., Garnett, C. E., & Senatore, F. (2021) · Circulation · doi:10.1161/circulationaha.120.053294 · Cited by 15
Li, H., Feng, Q., Tsoi, M. F., Fei, Y., & Cheung, B. M. Y. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa065 · Cited by 14
Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review
Oliva, A., Cao, D., Spirito, A., Nicolas, J., Pileggi, B., Kamaleldin, K. M., Vogel, B., & Mehran, R. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s391400 · Cited by 20
Cardiovascular events in individuals treated with sulfonylureas or dipeptidyl peptidase 4 inhibitors
Turchin, A., Petito, L. C., Hegermiller, E., Carnahan, R., DeVries, A., Goel, S., Lansang, M. C., McDonnell, M. E., Nair, V., Priest, E., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.23067 · Cited by 14
Novel approaches to P2Y 12 inhibition and aspirin dosing
Parker, W. A., & Storey, R. F. (2020) · Platelets · doi:10.1080/09537104.2020.1714574 · Cited by 15
Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease
Parker, W. A., Gorog, D. A., Geisler, T., Vilahur, G., Sibbing, D., Rocca, B., & Storey, R. F. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa165 · Cited by 15
Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
Berg, D. D., Moura, F. A., Bellavia, A., Scirica, B. M., Wiviott, S. D., Bhatt, D. L., Raz, I., Bohula, E. A., Giugliano, R. P., Park, J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.031 · Cited by 14
Self-citationLi, X., Jia, Z., & Yan, Y. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.01.060 · Cited by 13
Hudzik, B., Błachut, A., Lesiak, M., Kubica, J., Wojakowski, W., & Gąsior, M. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0198 · Cited by 20
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances
Carlin, S., de Vries, T. A. C., Budaj, A., & Eikelboom, J. W. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0283 · Cited by 16
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis
Bonaca, M. P., Bhatt, D. L., Simon, T., Fox, K. M., Mehta, S. R., Harrington, R. A., Leiter, L. A., Capell, W. H., Held, C., Himmelmänn, A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.377 · Cited by 13
Self-citationMedical Therapy for Peripheral Artery Disease
Canonico, M. E., Hess, C. N., Rogers, R. K., & Bonaca, M. P. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02065-y · Cited by 14
Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials
Linden, K., Mailey, J. A., Kearney, A., & Menown, I. B. A. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01355-5 · Cited by 13
Maggioni, A. P., Dondi, L., Andreotti, F., Ronconi, G., Calabria, S., Piccinni, C. P., Pedrini, A., Esposito, I., & Martini, N. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211026390 · Cited by 12
Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients
Gager, G. M., Jilma, B., Winter, M., Hengstenberg, C., Lang, I. M., Toma, A., Prüller, F., Wallner, M., Kolesnik, E., von Lewinski, D., et al. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13304 · Cited by 14
Calderone, D., Capodanno, D., & Angiolillo, D. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1792293 · Cited by 12
Liu, Z., Tian, R., Wang, Y., Chen, Q., Li, J., Xu, L., & Zhang, S. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1713375 · Cited by 13
Drexel, H., Pocock, S., Lewis, B. S., Saely, C. H., Kaski, J. C., Rosano, G. M. C., Tautermann, G., Huber, K., Dopheide, J. F., MADER, A., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab048 · Cited by 12
Melo, M., Gavina, C., Silva‐Nunes, J., Andrade, L., & Carvalho, D. M. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00698-5 · Cited by 13
Antiplatelet Therapy in Patients with Coronary Disease and Type 2 Diabetes
Bates, E. (2019) · New England Journal of Medicine · doi:10.1056/nejme1910813 · Cited by 12
Sandner, S. E., Gaudino, M. F. L., Redfors, B., Angiolillo, D. J., Ben‐Yehuda, O., Bhatt, D. L., Fremes, S. E., Lamy, A. L., Marano, R., Mehran, R., et al. (2024) · EuroIntervention · doi:10.4244/eij-d-23-00699 · Cited by 11
Self-citationChinese expert consensus on anti-thrombotic therapy for pan-vascular diseases (2023 edition)
Chinese College of Cardiovascular Physicians (2024) · Cardiology Plus · doi:10.1097/cp9.0000000000000079 · Cited by 12
Croix, G. R. S., Lacy, S. C., Gazzhal, A., Ibrahim, M., Gjergjindreaj, M., Pérez, J., Shehadeh, M., Vedantam, K., Torres, C. A., Beohar, N., et al. (2022) · Journal of Interventional Cardiology · doi:10.1155/2022/3111840 · Cited by 16
Correlation Between Low THBS3 Expression in Peripheral Blood and Acute Myocardial Infarction
Chen, Y., Meng, H., Meng, X., Yan, Z., Wang, J., & Meng, F. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2710291 · Cited by 13
Hommels, T. M., Hermanides, R. S., Fabris, E., & Kedhi, E. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01844-1 · Cited by 12
Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes
Sidhu, M. S., Lyubarova, R., Bangalore, S., & Bonaca, M. P. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.12.005 · Cited by 10
Weissler, E. H., Aboyans, V., Bauersachs, R. M., Brodmann, M., Nikol, S., Debus, S. E., Patel, M. R., & Jones, W. S. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.01.035 · Cited by 11
Chen, P., Feng, W.-H., Ho, M.-Y., Su, C.-H., Huang, S.-W., Cheng, C.-W., Yeh, H., Chen, C.-P., Huang, W., Fang, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061657 · Cited by 11
Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes
Bates, E. (2020) · JAMA · doi:10.1001/jama.2020.16238 · Cited by 10
Kitt, K., Murphy, R., Clarke, A., Reddin, C., Ferguson, J. P., Bosch, J., Whiteley, W. N., Canavan, M. D., Judge, C. S., & O'Donnell, M. J. (2023) · Age and Ageing · doi:10.1093/ageing/afad197 · Cited by 14
Myers, R. A., Ortel, T. L., Waldrop, A., Cornwell, M., Newman, J. D., Levy, N., Barrett, T. J., Ruggles, K. V., Sowa, M. A., Davé, S. S., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319759 · Cited by 9
Zheng, B., Huo, Y., Lee, S. W. L., Sawhney, J. P. S., Kim, H.-S., Krittayaphong, R., Pocock, S., Nhân, V. T., Garcia, A. A., Chin, C. T., et al. (2020) · Clinical Cardiology · doi:10.1002/clc.23400 · Cited by 9
Cainzos‐Achirica, M., Anugula, D., Mszar, R., Grandhi, G. R., Patel, K. V., Bittencourt, M. S., Blankstein, R., Blaha, M. J., Blumenthal, R. S., Ray, K. K., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.09.006 · Cited by 8
Self-citationCalderone, D., Ingala, S., Mauro, M. S., Angiolillo, D. J., & Capodanno, D. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.2020100 · Cited by 11
Zhang, L., Chen, L., You, X., Li, M., Shi, H., Sun, W., Leng, Y., Xue, Y., & Wang, H. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.153953 · Cited by 9
Antiplatelet Therapy and Platelet Activity Testing for Neurointerventional Procedures
Fukuda, K. A., Beaman, C. B., & Szeder, V. (2024) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.124.001376 · Cited by 8
Montero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicoechea, M., et al. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.04.005 · Cited by 18
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease
Tian, J., Wang, Z., Wang, Y., Wang, F., Peng, X., Xiao, J., Li, C., Hou, X., Tong, Q., Yu, X., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2517588 · Cited by 12
Self-citationD’Amario, D., Galli, M., Restivo, A., Canonico, F., Vergallo, R., Migliaro, S., Trani, C., Burzotta, F., Aurigemma, C., Laborante, R., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad092 · Cited by 8
Antiplatelet therapies in diabetes
Sagar, R. C., Naseem, K. M., & Ajjan, R. (2020) · Diabetic Medicine · doi:10.1111/dme.14291 · Cited by 11
Liu, M., Zhuang, X., Chen, X., Zhang, S., Yang, D.-Y. D., Zhong, X., Xiong, Z., Lin, Y., Zhou, H., Fan, Y., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13324 · Cited by 7
Verdoia, M., Savonitto, S., Dudek, D., Kedhi, E., & Luca, G. D. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106828 · Cited by 8
Optimal medical therapy after coronary artery bypass grafting: a primer for surgeons
Eikelboom, R., Amir, T., Gupta, S. K., & Whitlock, R. P. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000889 · Cited by 9
Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk
Espinoza, C., & Mukherjee, D. (2021) · Heart International · doi:10.17925/hi.2021.15.1.26 · Cited by 9
Galli, M., Rollini, F., Been, L. F., Zenni, M. M., Angiolillo, D. J., & Franchi, F. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02696-4 · Cited by 8
Wittbrodt, E. T., Bhalla, N. P., Sundell, K. A., Gao, Q., Dong, L., Cavender, M. A., Hunt, P. R., Wong, N. D., & Mellström, C. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.133 · Cited by 7
Ticagrelor as an Alternative Antiplatelet Therapy in Cardiac Patients Non-Sensitive to Aspirin
Khan, H., Gallant, R. C., Jain, S., Al-Omran, M. A., de Mestral, C., Greco, E., Wheatcroft, M., Alazonni, A., Abdin, R., Rand, M. L., et al. (2020) · Medicina · doi:10.3390/medicina56100519 · Cited by 9
Pharmacology before, during and after percutaneous coronary intervention
Zaman, A., & Aleem, Q. (2020) · Heart · doi:10.1136/heartjnl-2019-315090 · Cited by 10
Kathman, S. J., Wheeler, J. J., Bhatt, D. L., Arnold, S. E., & Lee, J. S. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12734 · Cited by 9
Self-citationMarcano, A. L., Gracida, M., Roura, G., Lara, J. G., Romaguera, R., Teruel, L., Fuentes, L., Muntané‐Carol, G., Meroño, O., Sosa, S. G., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1057331 · Cited by 8
Practical guidelines for the prevention and management of diabetic foot disease in China
Luo, G., Liu, Y., & Wang, A. (2025) · Burns & Trauma · doi:10.1093/burnst/tkaf064 · Cited by 15
Self-citationAntiplatelet therapy for coronary artery disease in 2023: current status and future prospects
Chandiramani, R., Spirito, A., Johnson, J. W., Mehta, A., Vogel, B., FAILLACE, R. T., & Mehran, R. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2201437 · Cited by 8
Blin, P., Darmon, P., Henry, P., Guiard, E., Bernard, M., Dureau‐Pournin, C., Maizi, H., Thomas‐Delecourt, F., Lassalle, R., Droz‐Perroteau, C., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01416-1 · Cited by 7
Parker, W. A., Sagar, R. C., Kurdee, Z., Hawkins, F., Naseem, K. M., Grant, P. J., Storey, R. F., & Ajjan, R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01427-y · Cited by 8
Tan, J. W. C., Chew, D. P., Tsui, K. L., Tan, D. S., Duplyakov, D. V., Hammoudeh, A. J., Zhang, B., Li, Y., Xu, K., Ong, P. J. L., et al. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.35 · Cited by 7
Self-citationSteg, P. G., Bhatt, D. L., James, S. K., Darlington, O. T., Hoskin, L., Simon, T., Fox, K. M., Leiter, L. A., Mehta, S. R., Harrington, R. A., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac032 · Cited by 8
Self-citationLin, Y., Cai, Z., Dong, S., Liu, H., Pang, X., Chen, Q., Yuan, J., & Geng, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.992376 · Cited by 8
Dobesh, P. P., Finks, S. W., & Trujillo, T. C. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.08.003 · Cited by 9
The Future of Aspirin Therapy in Cardiovascular Disease
Bhatt, D. L., & Pollack, C. V. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.019 · Cited by 6
Self-citationMarques, G. L., Albuquerque, A. M., Romaniello, G., Bozzi, F. P. L., da Cunha, G. P., Andraus, G. S., Hastreiter, G., Maniesi, B. D. P., Baena, C. P., & Guedes, M. H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1040936 · Cited by 6
Spagnolo, M., Angiolillo, D. J., & Capodanno, D. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2272595 · Cited by 7
Direct-acting Anticoagulants in Chronic Coronary Syndromes
Sorbets, E., & Steg, P. G. (2020) · European Cardiology Review · doi:10.15420/ecr.2018.24.2 · Cited by 7
Self-citationNo Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials
Sabatine, M. S., Hiatt, W. R., Goto, S., Johnston, S. C., Bonaca, M. P., Steg, P. G., Bhatt, D. L., Cannon, C. P., Andersson, M. V., & Wallentin, L. C. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.02.009 · Cited by 6
Self-citationCost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease
Wu, B. Y., & Shi, L. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa082 · Cited by 8
Барбараш, О. Л., Кашталап, В. В., & Шибанова, И. А. (2020) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2020-08-08 · Cited by 6
Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada
Lordkipanidzé, M., Marquis‐Gravel, G., Tanguay, J., Mehta, S. R., & So, D. Y. F. (2020) · CJC Open · doi:10.1016/j.cjco.2020.11.021 · Cited by 6
Self-citationCoronary revascularization in patients with stable coronary disease and diabetes mellitus
Bhat, S. Z., Yatsynovich, Y., & Sharma, U. C. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/14791641211002469 · Cited by 7
Polyunsaturated fatty acids in cardiovascular diseases: uncertainty prevails
Siniarski, A., & Gajos, G. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16066 · Cited by 7
Yuan, X., Li, J., Lei, L., Zhang, L., Chen, K., Chu, Q., Feng, W. E. I., Wang, X., Wang, X., Xu, F., et al. (2026) · BMJ · doi:10.1136/bmj-2025-088939 · Cited by 5
Self-citationZhang, C., & Wang, X. (2023) · Aging Medicine · doi:10.1002/agm2.12234 · Cited by 4
Russo, J. J., Yan, A. T.-K., Pocock, S., Brieger, D. B., Owen, R., Sundell, K. A., Bagai, A., Granger, C. B., Cohen, M. G., Yasuda, S., et al. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.10.024 · Cited by 5
Self-citationAntiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention
Alkhalil, M., Džavík, V., Bhatt, D. L., Mehran, R., & Mehta, S. R. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01645-0 · Cited by 7
Self-citationAntithrombotic Treatment in Coronary Artery Disease
Siasos, G., Tsigkou, V., Bletsa, E., Stampouloglou, P. K., Oikonomou, E. K., Kalogeras, K. I., Κατσαρού, Ο., Pesiridis, T., Vavuranakis, Μ., & Tousoulis, D. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230830105750 · Cited by 5
Antithrombotic Treatment for Chronic Coronary Syndrome: Evidence and Future Perspectives
Kulasingam, A., Pareek, M., Gragnano, F., Würtz, M., Pryds, K., Calabrò, P., & Grove, E. L. (2024) · Cardiology · doi:10.1159/000537706 · Cited by 5
Montero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicechea, M., et al. (2024) · Nefrología · doi:10.1016/j.nefro.2024.11.002 · Cited by 5
Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD
Govsyeyev, N., Nehler, M. R., Hiatt, W. R., & Bonaca, M. P. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-1264-z · Cited by 5
Feng, Q., Tsoi, M. F., Fei, Y., Cheung, C. L., & Cheung, B. M. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-00105-z · Cited by 5
Preoperative Use of Aspirin in Total Knee Arthroplasty: Safe or Not?
Zeng, L., Xiang, S., Du, Y., Zhang, M., Bian, Y., Feng, B., & Weng, X. (2022) · Orthopaedic Surgery · doi:10.1111/os.13321 · Cited by 5
Sandner, S. E., Kastrati, A., Niessner, A., Böning, A., Zeymer, U., Conradi, L., Danner, B. C., Zimpfer, D., Färber, G., Manville, E., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.10.166 · Cited by 5
Saudi Heart Association Guidelines on Best Practices in the Management of Chronic Coronary Syndromes
Alshammeri, O., Saif, S. A., Alshehri, H. Z., Alasng, M., Qaddoura, F., Shehri, M. A., Turkistani, Y., Tash, A. A., Alharbi, W., Alqahtani, F., et al. (2022) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1320 · Cited by 7
Wang, L., Xiang, L., Piao, S., Gong, X., Zhou, W.-X., Feng, W., Li, H.-L., Li, L., Wei, A., Zhu, Q., et al. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s309419 · Cited by 5
Real‐World Comparison of Ticagrelor and Clopidogrel: Rosetta Stone or Lost in Translation?
Bergmark, B. A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017888 · Cited by 5
Oliva, A., Angiolillo, D. J., Valgimigli, M., Cao, D., Sartori, S., Bangalore, S., Bhatt, D. L., Campo, G. C., Chehab, B., Choi, J. W., et al. (2025) · EuroIntervention · doi:10.4244/eij-d-24-00897 · Cited by 5
Self-citationPolypharmacology in Clinical Applications: Cardiovascular Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_4 · Cited by 4
Zhu, H., Xu, X., Wang, H., Chen, Q., Fang, X., Zheng, J., Gao, B., Tong, G., Zhou, L., Chen, T., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1040473 · Cited by 5
Metadata
- Authors
- Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., Leonsson-Zachrisson, M., Liu, Y., Opolski, G., Zateyshchikov, D., Ge, J., Nicolau, J. C., Corbalán, R., Cornel, J. H., Widimský, P., & Leiter, L. A.
- Affiliations
- From the French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Université de Paris, INSERM Unité 1148 (P.G.S.), Assistance Publique–Hôpitaux de Paris (P.G.S., T.S.), Hôpital Saint Antoine, Department of Clinical Pharmacology, Unité de Recherche Clinique (T.S.), and Sorbonne Université (T.S.) — all in Paris; the National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, London (P.G.S., K.F.); Brigham and Women’s Hospital Heart and...
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Uppsala University (SE)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-03
- Volume
- 381
- Issue
- 14
- Pages
- 1309-1320
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2970797239
- Cited by
- 365
- References
- 32
- Citations by year
- 2026: 27 · 2025: 30 · 2024: 34 · 2023: 48 · 2022: 56 · 2021: 81 · 2020: 75 · 2019: 12
- FWCI
- 40.45
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Florence Research (University of Florence) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Warwick Research Archive Portal (University of Warwick) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, stable coronary artery disease, type 2 diabetes, antiplatelet therapy, aspirin, major bleeding, intracranial hemorrhage, cardiovascular events, irreversible harm, treatment discontinuation, P2Y12 inhibitors, elderly patients, cardiovascular risk stratification, bleeding risk assessment, risk-benefit assessment
- MeSH terms
- Ticagrelor, Aged, Aspirin, Coronary Artery Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Incidence, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.